X0202 SCHEDULE 13G/A 0000919574-26-006888 0001758892 XXXXXXXX LIVE 1 Ordinary Shares, nominal value 0.05 GBP per share 10/05/2026 0001479615 Silence Therapeutics plc G8128Y157 12 HAMMERSMITH GROVE OFFICE 205 LONDON X0 W6 7AP Rule 13d-1(c) Tetragon Financial Group Limited Y7 0.00 9878565.00 0.00 9878565.00 9878565.00 N 5.3 OO Represented by 3,292,855 ADSs (as defined in Item 2(a)) (includes 1,500,000 Shares (as defined in Item 2(a)) (underlying 500,000 ADSs) issuable upon exercise of call options). Tetragon Financial Management LP DE 0.00 9878565.00 0.00 9878565.00 9878565.00 N 5.3 IA PN Represented by 3,292,855 ADSs (includes 1,500,000 Shares (underlying 500,000 ADSs) issuable upon exercise of call options). Patrick G. G. Dear X0 0.00 9878565.00 0.00 9878565.00 9878565.00 N 5.3 IN Represented by 3,292,855 ADSs (includes 1,500,000 Shares (underlying 500,000 ADSs) issuable upon exercise of call options). Reade E. Griffith X0 0.00 9878565.00 0.00 9878565.00 9878565.00 N 5.3 IN Represented by 3,292,855 ADSs (includes 1,500,000 Shares (underlying 500,000 ADSs) issuable upon exercise of call options). Silence Therapeutics plc 12 Hammersmith Grove, London W6 7AP, United Kingdom This statement is filed by: i. Tetragon Financial Group Limited ("Tetragon"), a Guernsey company, with respect to the Ordinary Shares, nominal value 0.05 GBP per share (the "Shares") held in the form of American Depositary Shares ("ADSs") and the Shares underlying ADSs issuable upon exercise of call options directly held by it; ii. Tetragon Financial Management L.P. ("Tetragon Manager"), a Delaware limited partnership, as the investment manager of Tetragon, with respect to the Shares held in the form of ADSs and the Shares underlying ADSs issuable upon exercise of call options directly held by Tetragon; iii. Patrick G. G. Dear ("Mr. Dear"), as principal to Tetragon Manager, with respect to the Shares held in the form of ADSs and the Shares underlying ADSs issuable upon exercise of call options directly held by Tetragon; and iv. Reade E. Griffith ("Mr. Griffith"), as principal to Tetragon Manager, with respect to the Shares held in the form of ADSs and the Shares underlying ADSs issuable upon exercise of call options directly held by Tetragon. Each ADS represents three Shares. This Amendment No. 1 amends and restates the original statement on Schedule 13G filed by the Reporting Persons on October 13, 2026. The address of the principal office of each of Tetragon and Messrs. Dear and Griffith is c/o Tetragon Partners UK LLP, 4 Sloane Terrace, London SW1X 9DQ, United Kingdom. The address of the principal office of Tetragon Manager is 399 Park Avenue, 22nd Floor, New York, New York 10022. Tetragon is a Guernsey company. Tetragon Manager is a Delaware limited partnership. Messrs. Dear and Griffith are citizens of the United Kingdom. Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 186,461,401 Shares outstanding, as reported in the Company's, Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 12, 2026 and in the Company's press release dated as of August 14, 2026, after giving effect to the completion of the offering and the full exercise of the underwriters' over-allotment option, all as described therein. 5.3% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). N See Item 2(a). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Tetragon Financial Group Limited /s/ Reade E. Griffith 10/13/2026 Tetragon Financial Management LP /s/ Reade E. Griffith 10/13/2026 Patrick G. G. Dear /s/ Patrick G.G. Dear 10/13/2026 Reade E. Griffith /s/ Reade E. Griffith 10/13/2026